TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31378628

Group type: COMPARATOR
Intervention: Morning chronotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher TOTFA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MUFA
Number of subjects: 0
Study: 28899731

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous physical-cognitive training
Number of subjects: 0
Study: 25224018

Group type: EXPERIMENTAL
Intervention: PNHA (topical gel application two times a week for a total of 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HA (topical application)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PNHA
Number of subjects: 39

Group type: COMPARATOR
Intervention: HA
Number of subjects: 39
Study: 24708617

Group type: EXPERIMENTAL
Intervention: Minimal contact web-guided Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Mobile-guided intervention comprising mindfulness, acceptance and value-based exercises
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Face-to-face group intervention using mindfulness, acceptance and value-based approach
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study: 22191856

Group type: EXPERIMENTAL
Intervention: Moxifloxacin punctum plug (MP)
Number of subjects: 20
Study: 20005965

Group type: EXPERIMENTAL
Intervention: 1q21 gain
Number of subjects: 91

Group type: COMPARATOR
Intervention: No 1q21 gain
Number of subjects: 91
Study: 17997263

Group type: EXPERIMENTAL
Intervention: Counselling intervention with standard exercise and nutrition information plus up to five face-to-face counselling sessions with a Physical Activity Specialist (PAS) and Registered Dietitian (RD) over a 6-month period
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual care (health promotion leaflet)
Number of subjects: 334
Study: 16046715

Group type: EXPERIMENTAL
Intervention: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Number of subjects: 48

Group type: COMPARATOR
Intervention: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with lifestyle activity (control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with lifestyle activity (control)
Number of subjects: 48
Study: 12525339

Group type: EXPERIMENTAL
Intervention: Presence of stressful life events (SLE)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no SLE)
Number of subjects: 236
Study: 10337449

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 0
Study: 8954300

Group type: EXPERIMENTAL
Intervention: Left corona radiata infarcts
Number of subjects: 64

Group type: COMPARATOR
Intervention: Right corona radiata infarcts
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pontine base infarcts
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dorsomedial portion of the pontine base lesions
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ventromedial portion of the pontine base lesions
Number of subjects: 64
Study: 1712803

Group type: EXPERIMENTAL
Intervention: Allergen challenge (single dose sprayed into one side of the nose)
Number of subjects: 9
Study: 6227877

Group type: EXPERIMENTAL
Intervention: Combination of ipratropium bromide (40 micrograms/puff) and fenoterol (100 micrograms/puff)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol (100 micrograms/puff)
Number of subjects: 12
Study: 31602965

Group type: EXPERIMENTAL
Intervention: Propofol (Group TIVA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 90
Study: 29558848

Group type: EXPERIMENTAL
Intervention: Nail varnish applied
Number of subjects: 43

Group type: COMPARATOR
Intervention: No nail varnish applied
Number of subjects: 43
Study: 26909904

Group type: EXPERIMENTAL
Intervention: modified BLUPIS (BLUPISM) procedure
Number of subjects: 110

Group type: COMPARATOR
Intervention: classic individuals (BLUPI)
Number of subjects: 110
Study: 24560036

Group type: EXPERIMENTAL
Intervention: School-located vaccination program
Number of subjects: 3144
Study: 23569986

Group type: EXPERIMENTAL
Intervention: Cisplatin chemotherapy (40-50 mg/day)
Number of subjects: 18
Study: 19951955

Group type: EXPERIMENTAL
Intervention: Experimental adjuvant treatments
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: New treatments for metastatic disease
Number of subjects: 236
Study: 17330176

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine (a type of ChEI)
Number of subjects: 0
Study: 15857723

Group type: EXPERIMENTAL
Intervention: Matrix Model (manualized treatment)
Number of subjects: 1016
Study: 11856087

Group type: EXPERIMENTAL
Intervention: Synthetic human motilin (2 pmol x min/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Synthetic human motilin (4 pmol x min/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12569793

Group type: EXPERIMENTAL
Intervention: Chongcao shenkang capsules 2.7 grams tid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (combined therapy with balanced salt solution and ribavirin)
Number of subjects: 150
Study: 7475162

Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 1: 2 mg/kg bolus, 1 mg/kg in oxygenator prime, 0.5 mg/kg/hr infusion)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 2: doubled doses)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Recombinant aprotinin (dosage level 2)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Recombinant aprotinin and Control group
Number of subjects: 84
Study: 2216190

Group type: EXPERIMENTAL
Intervention: Second-look laparotomy
Number of subjects: 131
Study: 7002430

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 10 mg daily for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 10 mg daily for 10 weeks
Number of subjects: 0
Study: 30596978

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with everolimus‐eluting stents
Number of subjects: 810

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 810
Study: 28060206

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Present Centered Therapy
Number of subjects: 129
Study: 25756917

Group type: EXPERIMENTAL
Intervention: Ankle aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study: 23951362

Group type: EXPERIMENTAL
Intervention: RAL+DRV/r
Number of subjects: 58

Group type: COMPARATOR
Intervention: LPV/r+TVD
Number of subjects: 58
Study: 21353329

Group type: EXPERIMENTAL
Intervention: Propranolol (2 to 2.5 mg/kg per day, divided in 3 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 20
Study: 19378635

Group type: EXPERIMENTAL
Intervention: Crossing the border to purchase medications (US residents)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Crossing the border to purchase medications (Ciudad Juarez residents)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Traveling to Mexico for dental care (US residents)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Traveling to Mexico for medical care (US residents)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Traveling to the United States for medications or health care (Mexican nationals)
Number of subjects: 1000
Study: 17544338

Group type: EXPERIMENTAL
Intervention: Cocaine experienced adults (CE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (for CE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy normal volunteers (HN)
Number of subjects: 17
Study: 15163331

Group type: EXPERIMENTAL
Intervention: Full dose hydrocortisone (10 mg twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Half-dose hydrocortisone (5 mg twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no glucocorticoid treatment)
Number of subjects: 10
Study: 11798229

Group type: EXPERIMENTAL
Intervention: Around-the-clock (ATC) opioid therapy, specifically controlled-release oral formulations (e.g. morphine, oxycodone, hydromorphone, hydrocodone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of opioids
Number of subjects: 0
Study: 9597370

Group type: EXPERIMENTAL
Intervention: Fig leaf decoction (FC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-sweet commercial tea (TC)
Number of subjects: 10
Study: 7930314

Group type: EXPERIMENTAL
Intervention: Behavioral algorithm for dietary fat intake < or = 30% of energy
Number of subjects: 744
Study: 3044723

Group type: EXPERIMENTAL
Intervention: Ajmaline (50‐75 mg i.v.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lidocaine (100‐200 mg i.v.)
Number of subjects: 31
Study: 29294429

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 28019686

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 160191
Study: 25746151

Group type: EXPERIMENTAL
Intervention: Biocompatible solutions
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard solutions
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Biocompatible solutions (sensitivity analysis)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard solutions (sensitivity analysis)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Biocompatible solutions (economic terms)
Number of subjects: 185
Study: 24277400

Group type: EXPERIMENTAL
Intervention: Enteral nutrition support (Ensure(R)) for 10 days before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous homogenized diet for 10 days before surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinical observations (nausea and vomiting)
Number of subjects: 60
Study: 21145052

Group type: EXPERIMENTAL
Intervention: Erythromycin 125 mg intravenously 30 minutes before endoscopy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo administered intravenously 30 minutes before endoscopy
Number of subjects: 102
Study: 19011436

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17908562

Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP) for 5 weeks at 25 hours/week
Number of subjects: 132

Group type: COMPARATOR
Intervention: Active Individual Therapy (AIT) for 5 weeks at 3 hours/week
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Active Individual Therapy (AIT)
Number of subjects: 132
Study: 15109089

Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11223449

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day) for 12 months
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day) for 3 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: VLDL-1 (100 microg apoB/ml)
Number of subjects: 11

Group type: COMPARATOR
Intervention: VLDL-1 vs VLDL-2 at 100 microg apoB/ml
Number of subjects: 11

Group type: COMPARATOR
Intervention: VLDL-1 vs IDL at 100 microg apoB/ml
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate (267 mg/day)
Number of subjects: 11
Study: 9326751

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7955804

Group type: EXPERIMENTAL
Intervention: Zolpidem (0.21 mg/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.04 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3296982

Group type: EXPERIMENTAL
Intervention: Insulin therapy withdrawn
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (diet and diabetes education without insulin withdrawal)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Insulin-withdrawal patients
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 49
Study: 29726050

Group type: EXPERIMENTAL
Intervention: Booklet containing dietary advice
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Booklet containing dietary advice plus tailored telephone intervention
Number of subjects: 492

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 492
Study: 27716696

Group type: EXPERIMENTAL
Intervention: Enriched breast milk feed (EBM + energy supplementation/fortification with human milk fortifier and Simyl medium‐chain triglyceride oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Expressed breast milk (EBM; 0.65 kcal/ml)
Number of subjects: 50
Study: 24897504

Group type: EXPERIMENTAL
Intervention: Prophylactic paracetamol treatment (24 hours starting at vaccination)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Therapeutic paracetamol treatment (6 hours after vaccination)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (no paracetamol)
Number of subjects: 496
Study: 23415202

Group type: EXPERIMENTAL
Intervention: Sequential postoperative antibiotic therapy (i.v. and oral)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional antibiotic treatment
Number of subjects: 27
Study: 20047618

Group type: EXPERIMENTAL
Intervention: EC‐MPS (720 mg b.i.d.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MMF (1000 mg b.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: EC‐MPS
Number of subjects: 24

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 24
Study: 18552164

Group type: EXPERIMENTAL
Intervention: CRT device switched on
Number of subjects: 32

Group type: COMPARATOR
Intervention: CRT device switched off
Number of subjects: 32
Study: 16098774

Group type: EXPERIMENTAL
Intervention: Venous grafts
Number of subjects: 2690

Group type: COMPARATOR
Intervention: Prosthetic grafts
Number of subjects: 2690
Study: 11871950

Group type: EXPERIMENTAL
Intervention: 1.0 microg x kg(‐1) remifentanil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 62
Study: 10443648

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg, administered orally at 0700 h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metyrapone (0.04 g/kg, administered orally at 2300 h the night before)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprazolam after Metyrapone
Number of subjects: 6
Study: 7809832

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 1969248

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 373906

Group type: EXPERIMENTAL
Intervention: Therapy A (2 AV followed by 2 CMF)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Therapy B (2 CMF followed by 2 AV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 110
Study: 30772980

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with biofeedback therapy (6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (recovered spontaneously)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with biofeedback therapy
Number of subjects: 50
Study: 28758341

Group type: EXPERIMENTAL
Intervention: Belatacept more-intensive
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Belatacept less-intensive
Number of subjects: 218

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Belatacept 4-weekly
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Belatacept 8-weekly
Number of subjects: 218
Study: 25281475

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23446897

Group type: EXPERIMENTAL
Intervention: Choline intake of 930 mg/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Choline intake of 480 mg/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Choline intake (both 480 mg/d and 930 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 47
Study: 20876346

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 214
Study: 19013258

Group type: EXPERIMENTAL
Intervention: Bovine collagen treatment at 15 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16963174

Group type: EXPERIMENTAL
Intervention: Desogestrel (75 microg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined oral contraceptive (ethinyl estradiol 20 microg plus desogestrel 150 microg)
Number of subjects: 40
Study: 15470992

Group type: EXPERIMENTAL
Intervention: Experimental Product E (10% carbamide peroxide gel containing potassium nitrate and sodium fluoride)
Number of subjects: 22
Study: 11471410

Group type: EXPERIMENTAL
Intervention: ACL reconstruction using autogenous, TETRA‐L3 augmented bone tendon bone graft
Number of subjects: 80
Study: 9428487

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 5156

Group type: COMPARATOR
Intervention: Single agent chemotherapy (platinum analogue or vinorelbine)
Number of subjects: 5156
Study: 7979615

Group type: EXPERIMENTAL
Intervention: Doppler perfusion index (DPI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intraoperative ultrasound
Number of subjects: 90
Study: 2721107

Group type: EXPERIMENTAL
Intervention: Sublingually administered buprenorphine (1, 2, and 4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered buprenorphine (1 and 2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1026545

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 0.6-1.8 g per day, given twice or three times daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 36
Study: 30021408

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28796313

Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 454
Study: 26294136

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) 120 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guaifenesin 400 mg
Number of subjects: 40
Study: 22641581

Group type: EXPERIMENTAL
Intervention: Vitamin D3 once a month (group D3M)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vitamin D2 once a month (group D2M)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Vitamin D2 in small fractionated doses at each HD session, 3 times per week (group D2S)
Number of subjects: 39
Study: 21448304

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 13 mg p-synephrine and 176 mg caffeine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-caloric placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing caffeine and p-synephrine
Number of subjects: 23
Study: 19653920

Group type: EXPERIMENTAL
Intervention: Encapsulated FeSO4 (10 mg Fe and 150 microg iodine)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: NutraFine RS (20 mg Fe)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (no fortification Fe)
Number of subjects: 279
Study: 17468120

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg on alternate days)
Number of subjects: 6377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6377
Study: 14695720

Group type: EXPERIMENTAL
Intervention: GEB-guided technique
Number of subjects: 240

Group type: COMPARATOR
Intervention: Digital technique
Number of subjects: 240

Group type: COMPARATOR
Intervention: Introducer tool (IT) technique
Number of subjects: 240
Study: 11343977

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and steroids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) in combination with mycophenolate mofetil (MMF) and steroids
Number of subjects: 50
Study: 9156357

Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion (0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min for 15 min each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 10
Study: 7701049

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) bolus injection of 6 mg benperidol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral administration as liquid
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral administration as tablets
Number of subjects: 13
Study: 3605732

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms X kg‐1 po
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diazepam 0.15 mg X kg‐1 po
Number of subjects: 30
Study: 31720903

Group type: EXPERIMENTAL
Intervention: Calibration sample (N = 2071)
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Validation sample (N = 1049)
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Factor 1
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Factor 2
Number of subjects: 3120